• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.


Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Show All Studies
Suggest Enhancement / Report Issue | Export to ExcelExport to Excel
Application Number P040012 S034
Current Protocol Accepted 08/02/2012
Study Name CANOPY Trial
Study Status Progress Adequate
General Study Protocol Parameters
Study Design Prospective Cohort Study
Study involve follow-up of premarket cohort (Y/N) No
Data Source Sponsor Registry
Comparison Group Objective Performance Criterion
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description The study is a prospective, multi-center, non-randomized, single arm, post-approval study of the approved RX   show the rest ...
Study Population Description The study population will include patients in whom a commercially available RX Acculink Carotid Stent   show the rest ...
Sample Size The study will enroll up to 350 clinical sites in the United States and at   show the rest ...
Data Collection Primary Endpoint: A composite rate of peri-procedural (within 30 days of the procedure) death and   show the rest ...
Followup Visits and Length of Followup 24-hours post-procedure period, 30-days, 1-year and annually for a total of 3 years

length of follow-up:   show the rest ...

CANOPY Trial Schedule

Report Schedule
Date Due
FDA Receipt
Reporting Status
6 month report 11/04/2011 08/30/2011 On Time
1 year report 05/05/2012 05/03/2012 On Time
18 month report 11/03/2012 10/31/2012 On Time
2 year report 05/05/2013 05/02/2013 On Time
3 year report 05/05/2014 04/21/2014 On Time
4 year report 05/05/2015 03/02/2015 On Time
5 year report 05/04/2016    

Show All Studies